- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04284839
심장 수술 후 직접 경구 항응고제 대 와파린 임상시험 (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
연구 개요
상세 설명
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Richard Whitlock, MD, PhD
- 전화번호: 40306 905-527-4322
- 이메일: richard.whitlock@phri.ca
연구 연락처 백업
- 이름: Emilie Belley-Cote, MD, MSc
- 전화번호: 40306 905-527-4322
- 이메일: emilie.belley-cote@phri.ca
연구 장소
-
-
-
Bonn, 독일, 53127
- 모집하지 않고 적극적으로
- University Hospital Bonn Heart Center
-
Essen, 독일, 45147
- 아직 모집하지 않음
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
연락하다:
- Matthias Thielmann, MD, PhD
-
수석 연구원:
- Matthias Thielmann, MD, PhD
-
Hamburg, 독일, 20246
- 모병
- University Medical Center Hamburg-Eppendorf
-
연락하다:
- Simon Pecha, MD
-
수석 연구원:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig, Saxony, 독일, 04289
- 모집하지 않고 적극적으로
- Heart Center Leipzig
-
-
Thuringia
-
Jena, Thuringia, 독일, Germany
- 모병
- University Hospital Jena
-
연락하다:
- Torsten Doenst, MD, PhD
-
수석 연구원:
- Torsten Doenst, MD, PhD
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 2C8
- 모병
- University of Alberta Hospital
-
수석 연구원:
- Steven Meyer, MD
-
연락하다:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6T 1Z3
- 모병
- University of British Columbia
-
수석 연구원:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R2H 2A6
- 모병
- St. Boniface Hospital
-
수석 연구원:
- Michael Yamashita, MD
-
연락하다:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John, New Brunswick, 캐나다, E2L4L2
- 모집하지 않고 적극적으로
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
- 모병
- Health Science Centre
-
수석 연구원:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury, Ontario, 캐나다, P3E 5J1
- 모병
- Health Sciences North Research Institute
-
수석 연구원:
- Bindu Bittira, MD
-
Hamilton, Ontario, 캐나다, L8L 2X2
- 모병
- Hamilton General Hospital
-
연락하다:
- Emilie Belley-Cote, MD, MSc
- 전화번호: 40306 905-527-4322
- 이메일: emilie.belley-cote@phri.ca
-
Toronto, Ontario, 캐나다, M5G 2C4
- 모병
- Toronto General Hospital
-
연락하다:
- Vivek Rao, MD
-
수석 연구원:
- Vivek Rao, MD
-
Toronto, Ontario, 캐나다, M4N 3M5
- 모병
- Sunnybrook Hospital
-
연락하다:
- Stephen Fremes, MD
-
수석 연구원:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal, Quebec, 캐나다, H1T 1C8
- 모병
- Montreal Heart Institute
-
연락하다:
- Philippe Demers, MD
-
수석 연구원:
- Philippe Demers, MD
-
Montreal, Quebec, 캐나다, H4J1C5
- 모병
- Hôpital Sacré-Coeur de Montréal
-
수석 연구원:
- Hugues Jeanmart, MD
-
연락하다:
- Hugues Jeanmart, MD
-
Québec, Quebec, 캐나다, G1V 4G5
- 모병
- IUCPQ-ULaval
-
연락하다:
- Eric Dumont, MD
-
수석 연구원:
- Eric Dumont, MD
-
-
-
-
Victoria
-
Fitzroy, Victoria, 호주, 3065
- 모병
- St Vincent's Hospital Melbourne
-
연락하다:
- Andrew Newcomb, MD
-
수석 연구원:
- Andrew Newcomb, MD
-
Parkville, Victoria, 호주, 3050
- 아직 모집하지 않음
- Royal Melbourne Hospital, University of Melbourne
-
연락하다:
- Alistair Royse, MD
-
수석 연구원:
- Alistair Royse, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
다른 이름들:
|
|
위약 비교기: Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Major Bleeding
기간: 30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
30일 및 90일에 뇌졸중 및 비중추신경계 전신 동맥 색전증의 복합.
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
주요 출혈
기간: 무작위화 후 90일
|
무작위화 후 90일
|
|
배액이 필요한 흉막 또는 심낭 삼출액
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
전신 동맥 색전증
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
허혈성 뇌졸중
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
심부정맥 혈전증
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
폐 색전증
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
수술 후 입원 기간
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
모든 원인으로 인한 사망
기간: 무작위화 후 6개월
|
무작위화 후 6개월
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
심근 경색증
기간: 무작위화 후 30일 및 90일
|
무작위화 후 30일 및 90일
|
|
|
무증상 판막 혈전증과 임상적으로 유의한 대동맥 판막 혈전증, 뇌졸중 또는 전신 색전증 사이의 연관성
기간: 90일
|
90일
|
|
|
Minor Bleeding
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
기간: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
기간: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
기간: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
기간: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Emilie Belley-Cote, MD, MSc, McMaster University
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- DANCE-2020
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .